eXmoor Pharma and Evox Therapeutics complete technology transfer programme
eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Evox Therapeutics have completed a technology transfer programme for Evox's exosome-enabled gene editing technology and specifically its MSH3-targeted programme for the treatment of Huntington’s disease.
Evox Therapeutics is advancing a pipeline of next-generation gene editing medicines targeting genetically driven neurodegenerative diseases, including Huntington's disease and amyotrophic lateral sclerosis. The programme involved the transfer and establishment of Evox’s proprietary manufacturing process and associated analytical methods at eXmoor’s Bristol facility. Completion of this phase provides the technical foundation for subsequent transfer into GMP and future clinical manufacture.
Exosome-delivered gene editing therapeutics are an emerging class of biologics, and this programme reflects the growing need to translate novel platforms into scalable manufacturing processes capable of supporting clinical development.
Lucy Foley, Chief Executive Officer of eXmoor Pharma, said:
Translating a novel platform of this kind into a robust and manufacturable process requires process development, analytical development and manufacturing expertise to be fully integrated from the outset. The successful establishment of Evox’s process and analytical methods at our Bristol facility reflects the strength of the collaboration between our teams and provides a clear foundation for the next stage of the programme.
Per Lundin, Chief Executive Officer of Evox Therapeutics, said:
As we continue to advance our pipeline of next-generation gene editing medicines, establishing strong technical and manufacturing foundations is an important part of our development strategy. eXmoor Pharma’s multidisciplinary expertise and collaborative approach made them the right partner to support this work as we progress our platform and Huntington’s disease programme towards clinical development.
